Summary
Eli Lilly and Company (LLY) filed an 8-K on May 2, 2017, detailing the results of their annual shareholder meeting held on May 1, 2017. The report indicates strong shareholder support for the company's director nominees and executive compensation practices. All five nominated directors were elected to three-year terms, with overwhelming 'For' votes. Additionally, shareholders provided an advisory 'Say-on-Pay' vote with a substantial majority in favor of the compensation paid to named executive officers, and overwhelmingly voted to hold these advisory votes annually. The company also received strong approval for the ratification of Ernst & Young as its principal independent auditor. Shareholder support was also evident for the Lilly Directors' Deferral Plan. Notably, a shareholder proposal requesting a report on political contributions was not approved, reflecting a divergence in shareholder sentiment on that particular matter. These results suggest a general alignment between management and a significant portion of the shareholder base regarding corporate governance and executive remuneration.
Key Highlights
- 1All five director nominees were overwhelmingly elected to serve three-year terms ending in 2020.
- 2Shareholders approved, on an advisory basis, the compensation paid to named executive officers (Say-on-Pay).
- 3Shareholders voted overwhelmingly in favor of holding advisory votes on executive compensation on an annual basis.
- 4Ernst & Young was ratified as Eli Lilly's principal independent auditor with significant shareholder approval.
- 5The Lilly Directors' Deferral Plan received strong shareholder approval.
- 6A shareholder proposal requesting a report on political contributions was not approved by the shareholders.
- 7Dr. John C. Lechleiter will retire from the board effective May 31, 2017.